Changes to Medicare Drug Plans for 2026

The landscape of Medicare prescription drug coverage is poised for considerable transformation in 2026, bringing a blend of policy-driven reforms, technical updates, and new beneficiary protections. These changes, shaped largely by ongoing implementation of the Inflation Reduction Act (IRA) of 2022, affect every facet of Medicare Part D – including out-of-pocket costs, coverage scope, accessibility, the structure of the benefit phases, and the rules under which both beneficiaries and plan sponsors will operate. The 2026 program year introduces further evolution, with finalized regulations from the Centers for Medicare & Medicaid Services (CMS), finalized manufacturer negotiations for high-cost drugs, and significant administrative updates for both enrollees and prescription drug plans.

Overview of 2026 Medicare Part D Changes

2026 is notable for the codification and operationalization of major IRA-driven reforms. CMS has finalized regulatory changes that include an increased annual out-of-pocket spending cap, updated deductible levels, expanded access and cost limits to insulin and vaccines, and – perhaps most prominent – the first-ever Medicare-negotiated drug prices for a set of high-expenditure, single-source medications. Additional modifications refine plan processes, streamline payment options, and add new safeguards, especially for chronically ill and low-income populations.

Key highlights of the 2026 changes include:

1. Annual out-of-pocket cap (TrOOP) for Part D increases to $2,100. After this cap, beneficiaries owe $0 for covered drugs for the rest of the year.
2. The maximum standard deductible rises to $615. Some plans may offer lower or $0 deductibles.
3. Initial implementation of Medicare drug price negotiations with lower prices for ten high-cost drugs.
4. Free, deductible-waived coverage for all adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) under Part D.
5. A $35-per-month cap on insulin copays, which may be lower if drug prices fall further via negotiation.
6. Automatic renewal of the Medicare Prescription Payment Plan, which smooths large out-of-pocket costs into predictable monthly payments.
7. Further restrictions and clarifications affecting plan appeals, provider notifications, and the use of supplemental benefits in Medicare Advantage (MA) plans.
8. Decreases in the number of available standalone Prescription Drug Plans (PDPs) and changes in the premium structure.

The following table summarizes key changes and their direct effects:

Change/Provision	2025 Status	2026 Status	Direct Effects
Out-of-pocket cap (TrOOP)	$2,000	$2,100	Lowers catastrophic risk for high users
Part D standard deductible	$590	$615	Higher upfront cost before plan pays
Medicare-negotiated drug prices	Not implemented	10 drugs covered	Lower costs for popular, expensive medications
Insulin cost sharing	$35 per month max	$35 or lower	Deductible waived, possible sub-$35 cost
Vaccine cost sharing	$0 for ACIP vaccines	$0, unchanged	No cost/deductible for ACIP adult vaccines
Prescription Payment Plan	Opt-in, annual	Auto-renew (opt-out)	Smoother budgeting; less admin burden
PDP plan availability	Declining	Down by 22%	Fewer choices; risk of plan disruptions
Premium stabilization subsidy	$15/month	$10/month	Risk of Plan D premium increases
Special Supplemental Benefits (MA)	Broader coverage	Stricter definition	Limits non-health-related extras
LIS (“Extra Help”) benchmark plans	90 plans	88 plans	Tightening options for low-income beneficiaries

The implications of these changes expand well beyond benefit design, as they influence the incentives of plan sponsors, pharmaceutical manufacturers, and the real-world experiences of people who rely on Medicare coverage every day.

Positive Changes to Medicare Drug Plans in 2026

1. Enhanced Financial Protection: Higher Out-of-Pocket Cap and End of “Donut Hole”

The 2026 $2,100 annual out-of-pocket spending cap for prescription medications is a direct carryover and incremental update from the 2025 cap, adjusted for average drug price inflation. Once this amount is reached, beneficiaries pay nothing out-of-pocket for covered Part D drugs for the remainder of the year. Unlike in past years, there are no further coinsurance or cost-sharing requirements in the “catastrophic” phase. This is a pronounced shift from earlier cost-sharing models, which saddled beneficiaries with ongoing coinsurance beyond catastrophic thresholds, sometimes leading to insurmountable annual pharmacy bills, especially among users of specialty or high-cost medications.

The elimination of the “donut hole” (coverage gap), fully realized in 2025, further streamlines cost predictability. All covered medications now progress smoothly from the deductible phase to initial coverage, and then directly to zero-cost catastrophic coverage once the cap is hit, simplifying budgeting and reducing risk for individuals with complex or chronic health needs.

2. Medicare Drug Price Negotiation Program

A landmark change for 2026 is the inaugural implementation of the Medicare Drug Price Negotiation Program. For the first time, Medicare directly negotiated prices with manufacturers for ten widely-used, high-expenditure single-source drugs – including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp/NovoLog. These drugs collectively accounted for roughly $56 billion in total Part D prescription drug costs in 2023, or about 20% of all Part D spending.

According to CMS, the negotiated prices represent discounts of 38–79% off 2023 list prices, with anticipated aggregate savings for Medicare and beneficiaries estimated at $6 billion in 2026, and $1.5 billion in direct beneficiary out-of-pocket savings for the same year alone. Every Medicare Part D plan must include these negotiated drugs on their formularies from 2026 forward, ensuring widespread access.

Not only does this initiative lower costs for the selected therapies, but it sets a precedent for subsequent negotiation cycles (with 15 more drugs set for negotiation in 2027), potentially driving broader long-term market savings and improved access to expensive and lifesaving treatments.

3. Predictable and Lower Insulin Costs

Insulin affordability remains critical for millions of Americans. The 2026 rules codify, for all Part D plans, a maximum cost-sharing amount for insulin that must not exceed the lesser of:

• $35 for a one-month supply,
• 25% of the Maximum Fair Price (MFP) established under Medicare’s drug negotiation program (if lower), or
• 25% of the plan-negotiated price.

Crucially, the deductible does not apply to insulin purchases, meaning even those who have not met their annual deductible still benefit from the $35 (or lower) cap from their first prescription fill each year. This policy not only enhances medication adherence among diabetes patients but also provides predictability for beneficiaries on fixed incomes or with chronic care needs.

4. Free Adult Vaccines Through Part D

The 2026 policies require all Part D plans to provide ACIP-recommended adult vaccines with no deductible and zero cost-sharing – even for out-of-network pharmacies and providers. Beneficiaries can access vaccines for influenza, COVID-19, shingles, pneumonia, and other evolving ACIP recommendations without financial barriers, supporting broad public health efforts and preventive care.

5. The Medicare Prescription Payment Plan: Auto-Renewal and Better Budgeting

Initially introduced in 2025, the Medicare Prescription Payment Plan allows members to smooth their out-of-pocket costs for covered prescriptions across the year, rather than potentially facing large upfront expenses at the pharmacy. For 2026, this plan is automatically renewed unless the enrollee opts out, further reducing administrative hassle and boosting consistent participation.

For those with high initial expenses or those concerned with budgeting, the Payment Plan is a boon: equal monthly payments help beneficiaries avoid “spikes,” prevent medication nonadherence, and provide relief during especially pricey quarters. There are built-in protections (no interest, no fees, two-month grace period for nonpayment) and easy opt-out provisions.

6. Enhanced D-SNP Integration and Special Needs Plan Experience

For dually eligible beneficiaries (Medicare & Medicaid), new federal requirements for Special Needs Plans (D-SNPs) begin phase-in by 2027, including integrated member ID cards (valid for both programs) and a streamlined, single health risk assessment for both benefit sets. These seemingly small changes simplify access, reduce paperwork, and support truly coordinated care for some of the most vulnerable users.

7. Prior Authorization Appeals & Coverage Protections

Medicare Advantage plans, a key vehicle for drug coverage, must now provide clearer appeals rights. Decisions made during the course of care (not just pre- or post-service) are now subject to standardized appeals rights and timelines, benefitting those whose services are reduced or denied mid-treatment. Plans are also restricted from retroactively revoking or downgrading inpatient admissions, unless fraud or administrative error is evident, reducing “bait-and-switch” risks for hospitalized patients.

8. Additional Transparency and Plan Finder Improvements

CMS is updating the Medicare Plan Finder to allow beneficiaries to see whether their doctors, specialists, or clinics are in a plan’s network – without leaving the tool for another website. This is crucial for informed shopping, especially as network accuracy remains a perennial concern. New requirements also push plans to keep provider directories up-to-date and make that information available for centralized displays.

9. Additional Payment Model Guardrails

CMS has added or codified operational requirements for timely claims data submission (Prescription Drug Event records) and for pharmacies to enroll in the new Medicare Transaction Facilitator Data Module, supporting accurate and prompt adjudication of claims and drug price adjustments for the negotiation program.

Negative Aspects of 2026 Medicare Drug Plan Changes

1. Modest Increases in Deductibles and Out-of-Pocket Caps

Both the standard deductible ($615) and the annual out-of-pocket cap ($2,100) rose modestly from their 2025 levels ($590 and $2,000, respectively). While these increases are incremental, they nonetheless mean that beneficiaries – especially those dependent on higher-cost drugs – must now cover a larger share of expenses before receiving full plan coverage.

For relatively healthy beneficiaries or those not routinely hitting the out-of-pocket cap, these increases feel like additional “nickel-and-diming,” particularly given other inflationary pressures affecting fixed incomes. While intended to keep pace with overall drug price trends, they represent a tangible erosion of first-dollar coverage for many.

2. Substantial Reduction in Standalone PDP Options

The number of available standalone Medicare Prescription Drug Plans (PDPs) is set to fall by 22%, from 464 in 2025 to 360 in 2026. This continues a multi-year trend: there are now barely half as many standalone PDPs as there were two years prior. The availability of premium-free “benchmark” plans for low-income (“Extra Help”) recipients has also dropped, with most states offering only one to four such options.

While CMS and plan sponsors assert that market consolidation allows for more robust, financially stable plans, the end user may experience disruption (e.g., forced plan changes, formulary differences, or adjusted pharmacy networks), particularly in rural areas and smaller states. Plan exits by major sponsors (such as Anthem) leave some members scrambling to re-enroll and heighten the risk of coverage lapses or medication disruptions.

3. Mixed or Rising Premiums for Many

Although CMS capped the base beneficiary premium increase at 6% (due to IRA provisions), and federal premium stabilization efforts continue, localized analysis shows a volatile environment for actual out-of-pocket premium costs. The federal stabilization subsidy for PDP premiums shrinks from $15/month in 2025 to $10/month in 2026, leaving insurers exposed to more plan liability and raising the ceiling on allowable year-over-year premium increases to $50, up from $35.

The actual consumer experience varies sharply by region and by plan, with some states and plans showing lower premiums, and others – especially in the volatile high-cost market segments – showing hikes of $10, $30, $50, or even $200+ per month. Beneficiaries on fixed incomes or with limited choices are particularly vulnerable.

Furthermore, the prevalence of “zero-premium” Medicare Advantage plans (which bundle Part D) continues to push the market toward these integrated plans, at the expense of standalone PDPs. The risk is that individuals who prefer traditional Medicare plus a standalone drug plan may find fewer viable or affordable choices going forward.

4. Potential Shifts in Formularies and Utilization Management

Mandatory inclusion of negotiated drugs on formularies is balanced by plan sponsors’ ongoing adjustments to class and tier structures, potentially resulting in restrictions, substitutions, or new prior authorization hurdles for drugs not directly affected by negotiation or by sponsors’ attempts to mitigate cost exposure.

Insurers, facing higher plan liability for catastrophic coverage under the new IRA rules, are incentivized to drive enrollees toward preferred (rebated) brands, generics, or biosimilars, and to tighten utilization management around pricey or non-negotiated products. Pharma sector experts have warned that even as patient cost protection increases for selected products, other formulary options could quietly shrink, especially in competitive or specialty categories.

5. Market Uncertainties and Transitional Confusion

The rapid pace of change – shrinking plan counts, updated enrollment rules, changing pharmacy networks, premium shifts, and evolving cost-sharing structures – means that many beneficiaries will need to “shop around” much more diligently. Experts agree that sticking with last year’s plan by default (a common behavior) may be increasingly risky as coverage, cost, and access dynamics shift.

For 2026, even more so than in previous years, careful review of the Annual Notice of Change (ANOC), use of impartial plan comparison tools, and potentially consulting with a licensed broker or State Health Insurance Assistance Program (SHIP) counselor is strongly recommended.

6. Reduction and Restriction of Certain Supplemental Benefits

For Medicare Advantage plans, the scope of allowable supplemental benefits – especially the “Special Supplemental Benefits for the Chronically Ill” (SSBCI) – has been narrowed for 2026. Non-healthy food, alcohol, tobacco, cosmetic procedures, life insurance, and general “membership” perks are outright prohibited as SSBCI offerings.

Though these guardrails are meant to preserve the benefit’s intent as a health-improvement tool, some critics argue that the removal of certain flexible supports (like food aid or transportation not explicitly health-linked) could disadvantage the most complex and marginalized populations.

7. Potential Consequences of the Drug Price Negotiation Program

While the negotiation program promises lower costs for selected drugs, some experts – such as Kirsten Axelsen of DLA Piper – have voiced concerns that it may ultimately reduce drug choice or disincentivize future investment in certain therapeutic categories. There are also early warnings of possible renegotiation-driven product shortages, as manufacturers re-evaluate market participation for drugs with steep mandated price cuts.

Further, as negotiation expands to cover more drugs, plans may further adjust their formularies, and non-negotiated competitive drugs may see changes in rebates, tiering, or coverage, with unclear downstream effects on both cost and access.

Impact on Coverage Scope, Costs, and Accessibility

Drug Coverage Scope

The core structure of Medicare Part D remains intact, but several updates change the real experience of coverage:

• Negotiated Drug Mandates: All Part D plans must cover all forms/dosages of the negotiated drugs on their formularies at the new, lower maximum fair price (MFP).
• Formulary Management: Plan sponsors retain flexibility to adjust coverage for non-negotiated drugs, within CMS rules for class coverage and “protected classes,” but are subject to CMS oversight to prevent abuses such as delayed or denied access to required therapies.
• Vaccine and Insulin Consistency: Uniform, zero or capped cost-sharing across all plans for vaccines and insulin provides stable ground for common preventive and chronic care needs.
• Supplemental Benefits: For MA plans, narrowed scope of special chronic-illness benefits may mean some previously available supports disappear.

Out-of-Pocket Costs

• Annual OOP Cap: The $2,100 spending cap provides a strong ceiling, particularly benefiting those with high drug use (e.g., complex chronic conditions, cancer, or specialty therapy needs).
• Deductible Increase: The $25 increase in the base deductible is not dramatic, but could affect lower-income or infrequent users as it comes “first-dollar.”
• Premium Variability: Regional and plan-level premium increases risk being hidden amid average stable or decreasing premium statistics; careful shopping is essential.

Accessibility and Enrollment

• Plan Shrinkage and Market Concentration: The reduction in standalone PDP choices, coupled with migration toward MA-PD plans, could limit rural or specialized access. Fewer benchmark plans for LIS participants increases the burden to shop and potentially pay premiums.
• Enrollment Rules: 2026 brings clarified language and simpler forms for plan selection, but the loss of some data fields (race, ethnicity, sexual orientation, gender identity) may reduce the ability to track and address equity issues.
• Provider Finder Tool: Improvements to the Medicare Plan Finder (Plan Compare) with network provider data should, in theory, reduce accidental out-of-network enrollments, but full rollout and reliability may take time.

Demographic Impacts: Seniors, Low-Income Individuals, and Those with Chronic Conditions

Seniors

As the primary demographic in Medicare, seniors experience direct consequences from all Part D changes:

• Financial Exposure: The raised OOP cap is universally beneficial; however, increased deductibles and premium volatility may hit those on fixed incomes.
• Plan Choice: The reduction in plan options could mean less scope for shopping around, especially for those with established pharmacy or physician networks.
• Preventive Health: Free adult vaccines lower barriers for seniors to receive recommended care, with demonstrable public health benefits.

Low-Income Beneficiaries

• Extra Help (“LIS”) Dynamics: Slight reduction in premium-free benchmark map plans tightens safety net access, potentially increasing premium obligations for some who have been auto-enrolled.
• Cost-Sharing Protections: LIS enrollees continue to receive generous prescription copay reductions and deductible waivers – $1.60 for generic and $4.90 for brand drugs at the lowest income level in 2026 – but narrowing plan choices may disrupt continuity.
• Payment Plan Relevance: For many low-income beneficiaries, the Prescription Payment Plan may be redundant, as their copays are already well below the $2,100 cap; however, it remains available to all.

Individuals with Chronic Conditions

• Predictability and Catastrophic Protection: For those requiring costly, ongoing medication regimes, the OOP cap, no-deductible insulin, and payment Plan smoothing are all critical positives.
• MA Plan Rules & Appeals: The new rules limiting retroactive downgrades in pre-approved inpatient stays protect those with complex needs from abrupt billings or care denials midway through hospitalizations.
• SSBCI Restrictions: Some previously available chronic care supports (e.g., certain foods, broad “wellness” supports) are now excluded from MA supplemental benefits, which may reduce holistic supports for managing long-term illness.

Expert Commentary and Analysis

Stakeholder reactions are mixed – praised for cost protections but wary of market and operational volatility. Key experts and commentators have provided the following insights:

• Adina Lasser (Alliance for Aging Research): Emphasizes the importance of annual active plan comparison, warning that failing to review and switch may cost seniors considerably more as plan and coverage structures change in 2026.
• Kirsten Axelsen (DLA Piper, Health Economist): Argues that the IRA’s negotiation structure may “shift costs elsewhere” and could prove “punitive” to some segments of the market, potentially reducing choices and long-run pharmaceutical innovation – a controversial but widely cited industry perspective.
• Jon Blum (USC Schaeffer Institute): Stresses that while automation and cost-sharing codification are progressing, actual oversight and program navigation require “human beings,” underscoring the risk of confusion amid administrative streamlining.
• Dr. Phillip Duncan (VCU, Cardiology): Calls out the cost barrier to critical therapies for some as a “travesty,” suggesting that out-of-pocket caps make a difference but that challenges persist, especially for therapies outside the negotiated list.
• CMS Policy Briefs and Actuarial Analyses: Suggest that, for non-LIS beneficiaries with chronic diseases, plan liability (and thus premium pressure) increases by 55–91% for common chronic medications and even more for specialty conditions. While the OOP caps protect the beneficiary, they reinforce the need for plans to tightly manage cost exposure, likely intensifying prior authorization, step therapy, and preferred product pressures.

Projections and Future Implications

Expansion of Drug Price Negotiation

The initial results – $1.5 billion in beneficiary savings and over $6 billion in total program savings from just ten drugs – are expected to grow as each subsequent year expands the roster of negotiated medications. Fifteen additional Part D drugs are scheduled for negotiation in 2027 (with new prices effective in 2028), and the inclusion of popular treatments (e.g., weight-loss drugs like Ozempic and Wegovy) could reshape the specialty therapy landscape.

Market Forces and Plan Design

Shrinking plan options, especially for standalone PDPs, suggest the market will continue consolidating. The divergence between standalone PDPs and MA-PDs will likely intensify, pushing more beneficiaries toward Medicare Advantage. While this offers simplicity and additional benefits for some, it reduces the availability of traditional Medicare plus PDP combinations.

Premium volatility could return to the fore once the temporary federal premium stabilization programs phase out. Depending on how insurers adapt to new plan liabilities, beneficiaries could see sharper year-over-year cost shocks without further policy intervention.

Plan Sponsor Strategies and Manufacturer Responses

Plan sponsors are expected to employ stricter formulary management, tighter step therapy, and more robust utilization oversight, particularly for non-negotiated or specialty drugs, to balance their increased liability under the redesigned IRA benefit structure. Manufacturers, meanwhile, may shift investment or rebate strategies to optimize competitiveness amid new pricing constraints.

Population-Level Health and Equity

If implemented with ongoing attention to network adequacy, formulary transparency, and supplemental benefit equity, the 2026 changes could significantly improve medication adherence and public health, especially in preventive care (vaccines) and chronic disease management (diabetes, heart failure, anticoagulation). However, care must be taken that market consolidation and plan design do not inadvertently reduce access for rural, low-income, or highly complex populations.

Overall

The 2026 Medicare drug plan reforms constitute the most significant set of changes since the inception of the Medicare Part D benefit in 2006. The overall direction is clear: increased protection for beneficiaries from catastrophic drug costs; real price reductions for a core group of high-spend medications; improved access to vaccines and chronic disease essentials; and smoother, more predictable out-of-pocket spending.

However, these advances come with trade-offs: higher first-dollar costs for many, a shrinking and less competitive plan market, localized spikes in premiums or loss of benchmark coverage, and the potential for complex ripple effects as plan sponsors, providers, and manufacturers recalibrate. Continued attention to the market’s evolving contours – by policymakers, consumer advocates, and beneficiaries themselves – will be vital to maximizing the promise of these reforms and mitigating unintended harms.

Beneficiaries – especially those with chronic conditions or financial vulnerabilities – must be especially vigilant during each year’s open enrollment, comparing plans against their medication lists, confirmed provider networks, and anticipated care needs. Helping hands from local SHIP counselors, brokers, and unbiased resources will be more critical than ever as 2026 brings both new opportunities and fresh complexities to the world of Medicare drug coverage.

Key Medicare Part D Changes for 2026

Change/Provision	Positive Impact	Negative Impact or Risk	Key Beneficiaries
$2,100 Annual OOP Cap (TrOOP)	Full drug cost protection after cap; no catastrophic coins.	Slight cap increase from 2025; higher up-front costs.	All high-cost users
$615 Standard Deductible	Predictable; capped max exposure.	Higher deductible; affects those with low drug spend.	All users
Drug Price Negotiation (10 drugs)	Deep discounts (38–79%); broad access; lower OOP and plan spend.	Only affects selected drugs; plans may retool formularies elsewhere.	Users of selected drugs
No-Cost ACIP Adult Vaccines	Free preventive care; removed access barriers.	N/A	All adults
Insulin Cap: $35 or lower	Affordability, no deductible required; possible lower-than-$35 copays.	Plan must cover types used; possible formulary narrowing.	Diabetes patients
Prescription Payment Plan	Budget smoothing; avoids large upfront bills; auto-renew.	Not needed for very low OOP patients; may complicate budgeting for some.	High OOP, variable spenders
PDP Choice Decline	Stronger, more stable plan designs.	Fewer choices; possible forced switches; less competition.	Standalone PDP enrollees
Premium Subsidy Decline	Cost control for government; transparency.	Higher possible premiums; $50 max increase for some.	Non-benchmark PDP users
LIS Benchmark Plan Drop	N/A	Fewer $0 premium options; tighter choice for Extra Help.	Low-income beneficiaries
MA/SSBCI Guardrails	Focused on health-related support; clarity.	Loss of certain flexible supports, e.g., non-healthy food.	Chronically ill in MA plans

References (24)

1. www.cms.gov
   Final CY 2026 Part D Redesign Program Instructions | CMS
2. www.kff.org
   A Current Snapshot of the Medicare Part D Prescription Drug Benefit – KFF
3. www.federalregister.gov
   Federal Register :: Medicare and Medicaid Programs; Contract Year 2026 …
4. www.aarpmedicareplans.com
   How Medicare Part D will change in 2026 | AARP Medicare plans
5. www.insurancesolutionsusa.com
   Medicare Part D in 2026: Understanding the $2,100 Out-of-Pocket Maximum …
6. www.kff.org
   Medicare Part D Premiums Are Decreasing for Many Stand-Alone Drug … – KFF
7. www.cms.gov
   Medicare Drug Price Negotiation Program: Negotiated Prices for Initial …
8. www.medicarerights.org
   Negotiated Prices Take Effect for Ten Drugs in 2026
9. pharmaphorum.com
   IRA negotiated prices revealed as Biden claims $6bn savings
10. www.forbes.com
    Take A Peek At Your 2026 Part D Drug Plans – Forbes
11. www.medicare.tools
    Insulin and Vaccine Costs in 2026 Medicare Part D: Key Rules Explained …
12. www.medicare.gov
    Insulin – Medicare
13. www.kff.org
    The Facts About the $35 Insulin Copay Cap in Medicare – KFF
14. planmedicare.com
    Big Medicare Changes for 2026: What You Need to Know About Insulin …
15. www.attacconsulting.com
    Key Provisions: 2026 Medicare Advantage & Part D Final Rule
16. www.medicare.tools
    Medicare Prescription Payment Plan (2026): Budgeting, Winners & Losers …
17. www.cms.gov
    Medicare Prescription Payment Plan | CMS
18. www.medicare.tools
    What to Expect from CMS’s 2026 Final Rule for Medicare Advantage & Part …
19. www.medicareplanning.com
    Medicare Part D 2026 – Medicare Planning
20. advisory.avalerehealth.com
    Part D Choices Continue to Shrink with Fewer PDPs in 2026
21. www.consumeraffairs.com
    Seniors face higher Medicare drug plan premiums in 2026
22. themedicarefamily.com
    Medicare Part D Prices Skyrocket in 2026: What You Need to Know
23. advisory.avalerehealth.com
    The New Stakeholder Economics of Part D After the IRA
24. www.hdrxservices.com
    Did You Know? 2026 Medicare Part-D Overview – HealthDirect